Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Biotechnology

Healthcare
$19.79 -3.08%

-$0.74 today

Market cap
$290.48M
Beta
1.38
P/E (TTM)
-15.6
EPS (TTM)
-$1.49
52W Low $7.78High $34.10

Volume 0.23M

Average 0.14M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$9.91M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$12.00M

FY 2025 · Annual

+174.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.57M)(7.83M)(8.89M)(15.79M)(19.36M)
Depreciation & Amortization3.61K3.61K3.61K3.61K1.78K
Deferred Income Tax(1.19M)(1.75M)000
Stock-Based Compensation660.58K1.74M2.38M7.25M6.8M
Change in Working Capital(385.17K)(122.27K)31.5K1.27M2.64M
Accounts Receivables00000
Inventory00000
Accounts Payables(526.73K)035.47K921.22K2.07M
Other Working Capital141.57K(122.27K)(3.97K)344.11K568.12K
Other Non-Cash Items1.19M1.75M000
Operating Cash Flow(4.29M)(6.2M)(6.48M)(7.27M)(9.91M)
Capital Expenditures0(3)033
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment00000
Common Stock Issued3.11M004.37M12M
Common Stock Repurchased0(7.54M)000
Dividends Paid00000
Other Financing Activities(275.15K)0000
Financing Cash Flow2.84M(7.54M)04.37M12M
Effect of Forex Changes00000
Net Change in Cash(1.46M)(13.74M)(6.48M)(2.9M)2.09M
Free Cash Flow(4.29M)(6.2M)(6.48M)(7.27M)(9.91M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$19.4M
+ D&A$1.8K
+ Stock-Based Comp$6.8M
+ Deferred Tax$0
+ Working Capital$2.6M
+ Other Non-Cash$0
= Operating Cash Flow-$9.9M
- Capex$3
= Free Cash Flow-$9.9M

Analysis

FY2025 free cash flow is -$9.9M. FCF conversion is 51.2% of net income. Operating cash flow was -$9.9M, with capex of $3. The largest bridge item is Stock-Based Comp at $6.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
DEFA14ADEFA14A filingOct 26, 2026
DEF 14ADEF 14A filingOct 26, 2026
ARSARS filingOct 26, 2026
10-QQuarterly reportAug 11, 2026
4Statement of changes in beneficial ownershipJul 30, 2026

Does GLSI generate free cash flow?

Greenwich LifeSciences, Inc. (GLSI) generated -$9.91M of free cash flow in fiscal 2025.

How much operating cash flow does GLSI produce?

Operating cash flow was -$9.91M, before capital expenditures of $3.00.